Amgen Inc. v. Sanofi, Aventisub LLC

 
DOCKET NO.
OP. BELOW
SUBJECT
Patent
AUTHOR
Gorsuch

Question(s) Presented

“Whether enablement is governed by the statutory requirement that the specification teach those skilled in the art to ‘make and use’ the claimed invention, 35 U.S.C. § 112, or whether it must instead enable those skilled in the art ‘to reach the full scope of claimed embodiments’ without undue experimentation—i.e., to cumulatively identify and make all or nearly all embodiments of the invention without substantial ‘time and effort.’”

Holding

“If a patent claims an entire class of processes, machines, manufactures, or compositions of matter, the patent’s specification must enable a person skilled in the art to make and use the entire class. In other words, the specification must enable the full scope of the invention as defined by its claims. . . . While we agree with Amgen that enablement is not measured against the cumulative time and effort it takes to make every embodiment within a claim, we are not so sure the Federal Circuit thought otherwise. That court went out of its way to say that it ‘do[es] not hold that the effort required to exhaust a genus is dispositive.’ . . . Instead, the court stressed, the problem it saw is the same problem we see: Amgen offers persons skilled in the art little more than advice to engage in ‘trial and error.’ . . . In any event, we review judgments of the lower courts, not statements in their opinions.”

Date
Proceedings and Orders
January 5, 2022
DISTRIBUTED for Conference of 1/21/2022.
January 11, 2022
Response Requested. (Due February 10, 2022)
January 14, 2022
Motion to extend the time to file a response is granted and the time is extended to and including March 14, 2022.
March 29, 2022
DISTRIBUTED for Conference of 4/14/2022.
April 18, 2022
The Solicitor General is invited to file a brief in this case expressing the views of the United States.
October 5, 2022
DISTRIBUTED for Conference of 10/28/2022.
October 31, 2022
DISTRIBUTED for Conference of 11/4/2022.
November 4, 2022
Petition GRANTED limited to Question 2 presented by the petition.
November 29, 2022
Blanket Consent filed by Respondent, Sanofi, et al.
December 1, 2022
Blanket Consent filed by Petitioner, Amgen Inc., et al.
December 15, 2022
Motion to extend the time to file the briefs on the merits granted. The time to file the joint appendix and petitioners' brief on the merits is extended to and including December 27, 2022. The time to file respondents' brief on the merits is extended to and including February 3, 2023.
January 17, 2023
Motion to dispense with printing the joint appendix filed by petitioner GRANTED.
January 31, 2023
SET FOR ARGUMENT on Monday, March 27, 2023.
February 3, 2023
Record requested from the U.S.C.A. for the Federal Circuit.
February 13, 2023
CIRCULATED
February 21, 2023
Motion of the Solicitor General for leave to participate in oral argument as amicus curiae, for divided argument, and for enlargement of time for oral argument GRANTED.
February 21, 2023
Motion of Chemistry and the Law Division of the American Chemical Society for leave to participate in oral argument as amicus curiae, for divided argument, and for enlargement of time for oral argument DENIED.
February 21, 2023
Record received from the U.S.C.A.-Federal Circuit. The record is available on PACER, except for confidential materials which were transmitted electronically.
February 27, 2023
Sealed records received electronically from the U.S.D.C.-Delaware. The remaining record is available on PACER.
March 16, 2023
Two copies of model exhibits from the record on appeal received from counsel for petitioners.
June 20, 2023